Esperoct is a recombinant factor VIII (FVIII) replacement therapy used for the routine prophylaxis and treatment of bleeding in adults and children aged 12 years and older with hemophilia A [1]. It is a high-purity, B-domain-deleted recombinant FVIII product [1].
How does Esperoct work?
Esperoct is designed to increase and maintain plasma FVIII activity levels, thereby reducing the frequency of bleeding episodes [1]. It is administered intravenously [1].
What are the approved uses of Esperoct?
Esperoct is approved for routine prophylaxis to prevent bleeding episodes in individuals with hemophilia A who are 12 years of age or older [1]. It is also used for the on-demand treatment of bleeding episodes in this patient population [1].
Who is Esperoct for?
Esperoct is indicated for adults and children aged 12 years and older diagnosed with hemophilia A [1].
What are the potential side effects of Esperoct?
The most common adverse reactions observed in clinical trials include injection site reactions and headache [1].
What is the efficacy of Esperoct in preventing bleeds?
In a clinical study, patients treated with Esperoct experienced a significantly reduced annualized bleeding rate (ABR) compared to their prior ABR on other prophylactic regimens [1]. The median ABR for treated patients was 0.0, with 84% of patients experiencing no or only one treated bleeding episode during the study [1].
When does Esperoct's patent expire?
Information regarding Esperoct's specific patent expiry dates is available from resources like DrugPatentWatch.com [2]. Patent protection for drugs is crucial for pharmaceutical companies, influencing market exclusivity and the eventual introduction of generic or biosimilar alternatives.
Are there alternative treatments for hemophilia A?
Yes, various treatment options exist for hemophilia A, including plasma-derived FVIII concentrates, other recombinant FVIII products, and non-FVIII-based therapies such as emicizumab [3]. The choice of treatment often depends on individual patient factors, bleeding history, and physician recommendation.
How does Esperoct compare to other FVIII treatments?
Esperoct is a high-purity, B-domain-deleted recombinant FVIII product, similar in mechanism to other recombinant FVIII therapies. Its specific advantages may lie in its formulation and pharmacokinetic profile, which aim to provide sustained FVIII activity for effective prophylaxis [1].
What is the pricing of Esperoct?
Pricing information for Esperoct is typically available through pharmaceutical distributors and healthcare providers, and can vary significantly based on factors such as geography, insurance coverage, and dosage [4].
What is the regulatory status of Esperoct?
Esperoct has received marketing authorization from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1].
What clinical data supports Esperoct's use?
Clinical trials have demonstrated Esperoct's efficacy in reducing bleeding episodes in patients with hemophilia A. Key data includes the reduction in annualized bleeding rates and the proportion of patients achieving zero or one treated bleed during treatment [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/esperoct/
[2] https://www.drugpatentwatch.com/
[3] https://www.mayoclinic.org/diseases-conditions/hemophilia/diagnosis-treatment/drc-20373321
[4] https://www.esperoct.com/